The resistance of SUM149 cancer stem cells to olaparib was reversed with RAD51 knockdown in vitro and in vivo, indicating a good potential for a combination of PARPi and RAD51i to alleviate PARPi resistance in BRCA-deficient tumors. This evidence concerns the gene RAD51 and cancer.